Key result
HB-ATV-8 intranasal vaccine shows favorable preclinical safety with no cardiotoxicity or mutagenicity.
Why the study?
Does the HB-ATV-8 intranasal vaccine demonstrate preclinical safety in animal and in vitro models?
Does the HB-ATV-8 intranasal vaccine demonstrate preclinical safety in animal and in vitro models?
Answers are grounded in this paper and cite their sources.
The HB-ATV-8 intranasal vaccine demonstrated a favorable preclinical safety profile, supporting its advancement into clinical trials for atherosclerosis and metabolic dysfunction-associated fatty liver disease.
The intranasal vaccine HB-ATV-8 contains the Seq-1 peptide (CHLLVDFLQSLS) as the active component within a nanoparticle formulation. It targets the cholesterol ester transfer protein (CETP) by inducing the formation of specific autoantibodies and a cellular antifibrotic response. It has demonstrated efficacy in preventing atherogenesis, liver steatosis, and fibrosis in preclinical models. Given that previously synthesized CETP inhibitors have been associated with increased cardiovascular risk, a preclinical safety assessment of HB-ATV-8 was conducted. Histopathological analysis of cardiac tissue from control and high-fat diet-fed rabbits treated with HB-ATV-8 revealed no inflammatory damage attributable to the vaccine. To further assess cardiac safety, an in vitro model using cells transfected with the human ether-à-go-go-related gene (hERG) potassium channel was employed to evaluate proarrhythmic potential through cardiac repolarization assessment. Patch-clamp electrophysiology confirmed that the HB-ATV-8 vaccine had no adverse effects on hERG channel kinetics. Genotoxicity was evaluated using the Ames test, which detects point mutations caused by base pair substitutions, additions, or deletions in DNA. The test was performed across multiple Salmonella typhimurium strains. The assays confirmed that HB-ATV-8 is not mutagenic. In addition, positron emission tomography (PET) imaging was performed in dwarf rabbits to evaluate glucose metabolism and systemic effects during vaccine treatment. PET imaging demonstrated that the HB-ATV-8 vaccine does not induce metabolic alterations and provided insights into its biodistribution. Our data fully justify advancing the HB-ATV-8 vaccine into clinical development, where its potential to address both atherosclerosis and metabolic dysfunction-associated fatty liver disease (MAFLD) will be evaluated in human studies.
No takes yet. Share an insight, caveat, or question.
Calixto-Tlacomulco et al. (2026) studied Atherosclerosis and Metabolic-Associated Fatty Liver Disease. HB-ATV-8 intranasal vaccine vs. Control was evaluated on Preclinical safety (cardiac histopathology, hERG channel kinetics, mutagenicity, and glucose metabolism). The HB-ATV-8 intranasal vaccine demonstrated preclinical safety with no inflammatory cardiac damage, no adverse hERG channel effects, and no mutagenicity in animal and in vitro models.
Synapse has enriched 10 related papers. Consider them for comparative context: